Compare Micron Technology, Inc. (MU) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Novavax Inc — how do they compare? Micron Technology, Inc. trades at $1,024.28 (market cap $1.17T), while Novavax Inc trades at $11.92 (market cap $1.82B). The key difference: Micron Technology, Inc. is far larger — about 642.9× Novavax Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Novavax Inc for 59 Days on average.
| MU | NVAX | |
|---|---|---|
Market Cap | $1.17T | $1.82B |
Volume | 29,425,906 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $1.21K | $12.56 |
52-Week Low | $181.60 | $6.22 |
Typical Hold Time | 48 Days | 59 Days |
Enterprise Value | $1.13T | $1.39B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,088, up 4.06% with strong bullish momentum, supported by consecutive earnings beats and robust AI-driven memory demand. The stock shows impressive fundamentals with 63.8% net margins and 91.77% ROE, while technical indicators signal bullish moving averages. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility, though growth deceleration concerns linger.
Outlook remains positive with analyst consensus at $1,590 price target (82.85% buy ratings), but risks include cyclical memory pricing, competitive pressures, and potential AI demand normalization. The stock's valuation appears reasonable with P/E of 13.94, supporting continued upside if execution persists.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
